BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering

Core Viewpoint - BriaCell Therapeutics Corp. has announced a public offering of 7,400,000 common shares and warrants, aiming to raise approximately $5.55 million to support its business objectives and working capital needs [1][2]. Group 1: Offering Details - The public offering price is set at$0.75 per share, with warrants having an exercise price of $0.9375, immediately exercisable for five years [1]. - The offering is expected to close on December 13, 2024, pending customary closing conditions [1]. - ThinkEquity is acting as the sole book-running manager for the offering [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital requirements, general corporate purposes, and advancing business objectives [2]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, filed with the U.S. SEC, and a final prospectus supplement will be made available [4].